









市场行情
/
股票
/
nasdaq-exas
/

Exact Sciences Corp

EXAS

101.560USD

-0.340-0.33%

收盘 12/31, 16:00（美东）报价延迟15分钟

19.24B总市值

亏损市盈率 TTM



Exact Sciences Corp

101.560

-0.340-0.33%

概览公司财务分析

概览

公司

财务

分析

关于 Exact Sciences Corp 公司

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp简介



公司代码EXAS

公司名称Exact Sciences Corp

上市日期Jan 30, 2001

CEOConroy (Kevin T)

员工数量6900

证券类型Ordinary Share

年结日Jan 30

公司地址5505 Endeavor Lane

城市MADISON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编53719

电话16082845700

网址https://www.exactsciences.com/

公司代码EXAS

上市日期Jan 30, 2001

CEOConroy (Kevin T)

Exact Sciences Corp公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.14M

-20.54%

Ms. Katherine S. (Kay) Zanotti

Independent Director

60.76K

-16.49%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+18.67%

Ms. Shacey Petrovic

Independent Director

28.90K

+22.97%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.04K

-11.04%

Ms. Leslie L. Trigg

Independent Director

17.17K

+80.75%

Ms. Kimberly J. (Kim) Popovits

Independent Director

16.38K

+156.47%

Mr. Aaron Bloomer

Chief Financial Officer, Executive Vice President

13.84K

Mr. Michael J. (Mike) Barber, M.D.

Independent Director

13.14K

+121.18%

Mr. James E. Doyle

Lead Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.14M

-20.54%

Ms. Katherine S. (Kay) Zanotti

Independent Director

60.76K

-16.49%

Mr. Daniel J. (Dan) Levangie

Independent Director

34.31K

+18.67%

Ms. Shacey Petrovic

Independent Director

28.90K

+22.97%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.04K

-11.04%

Ms. Leslie L. Trigg

Independent Director

17.17K

+80.75%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Commercial

387.50M

47.78%

Medicare Parts B & C

274.49M

33.84%

Other

93.84M

11.57%

International

55.26M

6.81%

地区USD

名称

营收

占比

United States (Country)

755.83M

93.19%

Outside of united states

55.26M

6.81%

业务

地区

业务USD

名称

营收

占比

Commercial

387.50M

47.78%

Medicare Parts B & C

274.49M

33.84%

Other

93.84M

11.57%

International

55.26M

6.81%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.36%

Capital World Investors

8.51%

Fidelity Management & Research Company LLC

8.11%

BlackRock Institutional Trust Company, N.A.

3.77%

Wellington Management Company, LLP

2.81%

其他

67.45%

持股股东

占比

The Vanguard Group, Inc.

9.36%

Capital World Investors

8.51%

Fidelity Management & Research Company LLC

8.11%

BlackRock Institutional Trust Company, N.A.

3.77%

Wellington Management Company, LLP

2.81%

其他

67.45%

股东类型

持股股东

占比

Investment Advisor

51.08%

Investment Advisor/Hedge Fund

27.76%

Hedge Fund

9.78%

Pension Fund

2.26%

Research Firm

2.00%

Individual Investor

0.91%

Private Equity

0.77%

Bank and Trust

0.59%

Sovereign Wealth Fund

0.48%

其他

4.37%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

1336

180.61M

95.18%

-13.94M

2025Q3

1352

180.95M

106.13%

-112.86K

2025Q2

1416

180.92M

107.16%

-6.42M

2025Q1

1400

186.11M

105.23%

-12.34M

2024Q4

1391

186.68M

107.44%

-1.15M

2024Q3

1351

188.95M

104.99%

+4.63M

2024Q2

1335

183.23M

95.81%

+15.73M

2024Q1

1330

166.64M

95.05%

-5.91M

2023Q4

1339

163.38M

96.52%

-2.83M

2023Q3

1319

166.02M

95.28%

+1.45M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

17.76M

9.36%

-101.97K

-0.57%

Sep 30, 2025

Capital World Investors

16.14M

8.51%

-2.06M

-11.31%

Sep 30, 2025

Fidelity Management & Research Company LLC

15.38M

8.11%

-7.90M

-33.94%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

7.15M

3.77%

+116.86K

+1.66%

Sep 30, 2025

Wellington Management Company, LLP

5.33M

2.81%

-6.68M

-55.63%

Sep 30, 2025

State Street Investment Management (US)

5.20M

2.74%

-183.75K

-3.42%

Sep 30, 2025

Citadel Advisors LLC

3.94M

2.08%

+3.51M

+805.07%

Sep 30, 2025

MFS Investment Management

3.82M

2.01%

+855.10K

+28.85%

Sep 30, 2025

Columbia Threadneedle Investments (US)

3.73M

1.96%

+3.35M

+899.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

3.31M

1.75%

+74.79K

+2.31%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

First Trust Nasdaq Lux Digi Health Solutions ETF

4.48%

Invesco Biotechnology & Genome ETF

3.72%

First Trust NYSE Arca Biotechnology Index Fund

3.72%

Alger Mid Cap 40 ETF

3.61%

Clough Select Equity ETF

3.13%

Clough Hedged Equity ETF

2.78%

iShares Health Innovation Active ETF

2.72%

State Street SPDR S&P Biotech ETF

2.32%

First Trust Indxx Medical Devices ETF

2.22%

ROBO Global Healthcare Technology & Innovation ETF

2.03%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比4.48%

Invesco Biotechnology & Genome ETF

占比3.72%

First Trust NYSE Arca Biotechnology Index Fund

占比3.72%

Alger Mid Cap 40 ETF

占比3.61%

Clough Select Equity ETF

占比3.13%

Clough Hedged Equity ETF

占比2.78%

iShares Health Innovation Active ETF

占比2.72%

State Street SPDR S&P Biotech ETF

占比2.32%

First Trust Indxx Medical Devices ETF

占比2.22%

ROBO Global Healthcare Technology & Innovation ETF

占比2.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Exact Sciences Corp的前五大股东是谁？



Exact Sciences Corp 的前五大股东如下：
The Vanguard Group, Inc.持有股份：17.76M，占总股份比例：9.36%。
Capital World Investors持有股份：16.14M，占总股份比例：8.51%。
Fidelity Management & Research Company LLC持有股份：15.38M，占总股份比例：8.11%。
BlackRock Institutional Trust Company, N.A.持有股份：7.15M，占总股份比例：3.77%。
Wellington Management Company, LLP持有股份：5.33M，占总股份比例：2.81%。